The aim of this study was to investigate the relationship between psychotic-like experiences (PLEs) assessed using the Community Assessment of Psychic Experience (CAPE) questionnaire and the pattern of cannabis use in a non-clinical sample collected by snowball sampling.
Methods:
Our sample was composed of 204 subjects, distributed into three groups by their cannabis use pattern: 68 were non-cannabis users, 40 were moderate cannabis users and 96 were daily cannabis users. We assessed the psychotic experiences in each group with the CAPE questionnaire; and then controlled for the effect of possible confounding factors like sex, age, social exclusion, age of onset of cannabis use, alcohol use and other drug use.
Results:
We found a significant quadratic association between the frequency of cannabis use and positive (β = −1.8; p = 0.004) and negative dimension scores (β = −1.2; p = 0.04). The first-rank and mania factors showed a significant quadratic association (p < 0.05), while the voices factor showed a trend (p = 0.07). Scores for the different groups tended to maintain a U-shape in their values for the different factors. When we adjusted for gender, age, social exclusion, age of onset of cannabis use, and use of alcohol and other drugs, only the first-rank experiences remained significant.
Conclusions:
We found there was a U-shaped curve in the association between cannabis use and the positive and negative dimensions of the CAPE score. We also found this association in mania and first-rank experiences.
AndréassonSAllebeckPEngströmA. (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet2: 1483–1486.
2.
ArseneaultL (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry184: 110–117.
3.
ArseneaultLCannonMPoultonR. (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Br Med J325: 1212–1213.
4.
BarajasAOchoaSObiolsJE. (2015) Gender differences in individuals at high risk of psychosis: A comprehensive literature review. Scientif World J2015: 1–13.
5.
BarkusEJStirlingJHopkinsRS. (2006) Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology39: 175–178.
6.
BarrigónMLGurpeguiMRuiz-VeguillaM. (2010) Temporal relationship of first-episode non-affective psychosis with cannabis use: a clinical verification of an epidemiological hypothesis. J Psychiatr Res44: 413–420.
7.
BhattacharyyaSCrippaJAAllenP. (2012) Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry69: 27–36.
8.
BhattacharyyaSFusar-PoliPBorgwardtS. (2009) Modulation of mediotemporal and ventrostriatal function in humans by Delta 9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry66: 442–451.
9.
CaspiAMoffittTECannonM. (2005) Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene X environment interaction. Biolog Psychiatry57: 1117–1127.
ColizziMIyegbeCPowellJ. (2015) Interaction between functional genetic variation of DRD2 and Cannabis use on risk of psychosis. Schizophr Bull41: 1171–1182.
12.
CoyleJT (2006) Substance use disorders and schizophrenia: a question of shared glutamatergic mechanisms. Neurotoxic Res10: 221–233.
13.
De WitLMVan StratenAVan HertenM. (2009) Depression and body mass index, a u-shaped association. BMC Public Health9: 14.
14.
Di FortiMMarconiACarraE. (2015) Proportion of patients in South London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry2: 233–238.
15.
European Monitoring Centre for Drugs and Drug Addiction (2014) European Drug Report 2014: Trends and developments. Available from: www.emcdda.europa.eu (accessed 17 December 2015).
16.
FirstMichael BSpitzer. (1996) Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington DC: American Psychiatric Press, Inc.
17.
Fonseca-PedreroEPainoMLemos-GiráldezS. (2012) Validation of the Community Assessment Psychic Experiences-42 (CAPE-42) in Spanish college students and patients with psychosis. Actas Españ Psiquiatría40: 169–176.
18.
González-PintoAVegaPIbáñezB. (2008) Impact of cannabis and other drugs on age at onset of psychosis. J Clin Psychiatry69: 1210–1216.
19.
GualAContelMSeguraL. (2001) El ISCA (Interrogatorio Sistematizado de Consumos Alcohólicos): un nuevo instrumento para la identificación prematura de bebedores de riesgo (The ISCA (Questionnaire of Systematized Alcohol Consumption): a new instrument for identification of at-risk drinkers). Med Clínica117: 685–689.
20.
GuimarãesFSChiarettiTMGraeffFG. (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology100: 558–559.
21.
HäfnerHMaurerKLöfflerW. (1993) The influence of age and sex on the onset and early course of schizophrenia. Brit J Psychiatry162: 80–86.
22.
HanssenMSSBijlRVVolleberghW. (2003) Self-reported psychotic experiences in the general population: a valid screening tool for DSM-III-R psychotic disorders?Acta Psychiatr Scandinav107: 369–377.
23.
HeinzADesernoLReininghausU (2013) Urbanicity, social adversity and psychosis. World Psychiatry12: 187–197.
24.
HenquetCVan OsJKuepperR. (2010) Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br J Psychiatry J Ment Sci196: 447–453.
25.
JohnsLCCannonMSingletonN. (2004) Prevalence and correlates of self-reported psychotic symptoms in the British population. Br J Psychiatry J Ment Sci185: 298–305.
26.
KellyYSackerAGrayR. (2009) Light drinking in pregnancy, a risk for behavioural problems and cognitive deficits at 3 years of age?Int J Epidemiol38: 129–140.
27.
KesslerRC (2004) The epidemiology of dual diagnosis. Biolog Psychiatry56: 730–737.
28.
KoningsMBakMHanssenM. (2006) Validity and reliability of the CAPE: a self-report instrument for the measurement of psychotic experiences in the general population. Acta Psychiatr Scand114: 55–61.
29.
KuepperRVan OsJLiebR. (2011) Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. Brit Med J342: d738.
30.
LopesCSRodriguesLCSichieriR (1996) The lack of selection bias in a snowball sampled case-control study on drug abuse. Int J Epidemiol25: 1267–1270.
MooreTHMZammitSLingford-HughesA. (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet370: 319–328.
33.
MorganCKirkbrideJHutchinsonG. (2008) Cumulative social disadvantage, ethnicity and first-episode psychosis: a case-control study. Psychol Med38: 1701–1715.
34.
MorganCJACurranHV (2008) Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry J Ment Sci192: 306–307.
35.
MossahebNBeckerJSchaeferMR. (2012) The Community Assessment of Psychic Experience (CAPE) questionnaire as a screening instrument in the detection of individuals at ultra-high risk for psychosis. Schizophr Res141: 210–214.
OchoaSUsallJCoboJ. (2012) Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treatm2012: 1–9.
38.
PoultonRCaspiAMoffittTE. (2000) Children’s self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch Gen Psychiatry57: 1053–1058.
39.
PowerBDDragovicMJablenskyA. (2013) Does accumulating exposure to illicit drugs bring forward the age at onset in schizophrenia?Austral NZ J Psychiatry47: 51–58.
40.
Ros-MorenteAVilagra-RuizRRodriguez-HansenG. (2011) Process of adaptation to Spanish of the Community Assessment of Psychic Experiences (CAPE). Act Españ Psiquiatría39: 95–105.
41.
RösslerWHengartnerMPAngstJ. (2012) Linking substance use with symptoms of subclinical psychosis in a community cohort over 30 years. Addict107: 1174–1184.
42.
RösslerWRiecher-RösslerAAngstJ. (2007) Psychotic experiences in the general population: A twenty-year prospective community study. Schizophr Res92: 1–14.
43.
RubinoTZamberlettiEParolaroD (2012) Adolescent exposure to cannabis as a risk factor for psychiatric disorders. J Psychopharmacol26: 177–188.
44.
Ruiz-VeguillaMBarrigónMLHernándezL. (2013) Dose–response effect between cannabis use and psychosis liability in a non-clinical population: Evidence from a snowball sample. J Psychiatr Res47: 1036–1043.
45.
SchnohrPO’KeefeJHMarottJL. (2015) Dose of jogging and long-term mortality: the Copenhagen City Heart Study. J Am Coll Cardiol65: 411–419.
46.
SchubartCDSommerIECFusar-PoliP. (2014) Cannabidiol as a potential treatment for psychosis. J Eur Coll Neuropsychopharmacol24: 51–64.
47.
ShakoorSZavosHMSMcGuireP. (2015) Psychotic experiences are linked to cannabis use in adolescents in the community because of common underlying environmental risk factors. Psychiatry Res227: 144–151.
48.
SkosnikPDSpatz-GlennLParkS (2001) Cannabis use is associated with schizotypy and attentional disinhibition. Schizophren Res48: 83–92.
49.
StefanisNCDelespaulPHenquetC. (2004) Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addict99: 1333–1341.
50.
StefanisNCHanssenMSmirnisNK. (2002) Evidence that three dimensions of psychosis have a distribution in the general population. Psycholog Med32: 347–358.
51.
Van GastelWAWigmanJTWMonshouwerK. (2012) Cannabis use and subclinical positive psychotic experiences in early adolescence: findings from a Dutch survey. Addiction107: 381–387.
52.
Van NieropMVan OsJGuntherN. (2012) Phenotypically continuous with clinical psychosis, discontinuous in need for care: Evidence for an extended psychosis phenotype. Schizophr Bull38: 231–238.
53.
Van OsJBakMHanssenM. (2002) Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol156: 319–327.
54.
Van OsJLinscottRJMyin-GermeysI. (2009) A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med39: 179.
55.
VerdouxHVan OsJ (2002) Psychotic symptoms in non-clinical populations and the continuum of psychosis. Schizophr Res54: 59–65.
56.
VerdouxHSorbaraFGindreC. (2003) Cannabis use and dimensions of psychosis in a non-clinical population of female subjects. Schizophr Res59: 77–84.
57.
WattersJK (1989) Targeted sampling: Options for the study of hidden populations. Social Problems36: 416–430.
58.
WeaverTMaddenPCharlesV. (2003) Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. Brit J Psychiatry J Mental Sci183: 304–313.
59.
WoodwardM (2005) Epidemiology: Study Design and Data Analysis. Boca Raton: Chapman and Hall.
60.
World Health Association (1993) Composite International Diagnostic Interview (CIDI) version1.1.
61.
ZuardiAWCrippaJASHallakJEC. (2006) Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res39: 421–429.
62.
ZuardiAWCrippaJASHallakJEC. (2012) A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharmaceut Design18: 5131–5140.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
